Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badanie kabozantynibu i niwolumabu w skojarzeniu z radioterapią u osób z rakiem nerkowokomórkowym z przerzutami do mózgu

13 listopada 2026 zaktualizowane przez: Memorial Sloan Kettering Cancer Center

Badanie fazy 1b dotyczące bezpieczeństwa jednoczesnego stosowania kabozantynibu i niwolumabu z radioterapią w leczeniu przerzutów do mózgu u pacjentów z przerzutowym rakiem nerkowokomórkowym

The purpose of this study is to find out whether the combination of cabozantinib, nivolumab, and radiation therapy is a safe and effective treatment that causes few or mild side effects in people with renal cell cancer that has spread to the brain. The researches will also look at how the study treatment affects the quality of life of participants. They will measure the quality of life by having participants complete questionnaires.

Przegląd badań

Status

Aktywny, nie rekrutujący

Warunki

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

2

Faza

  • Faza 1

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • New Jersey
      • Basking Ridge, New Jersey, Stany Zjednoczone, 07920
        • Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
      • Middletown, New Jersey, Stany Zjednoczone, 07748
        • Memorial Sloan Kettering Monmouth (All Protocol Activities)
      • Montvale, New Jersey, Stany Zjednoczone, 07645
        • Memorial Sloan Kettering Bergen (All Protocol Activities)
    • New York
      • Commack, New York, Stany Zjednoczone, 11725
        • Memorial Sloan Kettering Cancer Suffolk - Commack (All Protocol Activities)
      • Harrison, New York, Stany Zjednoczone, 10604
        • Memorial Sloan Kettering Westchester (All Protocol Activities)
      • New York, New York, Stany Zjednoczone, 10065
        • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
      • Uniondale, New York, Stany Zjednoczone, 11553
        • Memorial Sloan Kettering Nassau (All Protocol Activities)

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  1. Unresectable advanced or metastatic clear cell or non-clear cell RCC; all histologies acceptable except for chromophobe RCC

  2. Brain metastases present, meeting the following criteria:

    1. At least 1 brain metastasis measuring ≥0.5cm in any dimension (intracranial RANO-BM measurable disease required)
    2. SRS is indicated per treating radiation oncologist
    3. Surgical intervention for brain metastases is not planned
  3. Able to undergo MRI Brain assessments for radiation planning.

  4. Availability of archival tissue that enables the definitive diagnosis of RCC, accompanied by an associated pathology report. If archival tissue cannot be obtained, PI to provide documented confirmation patient can still enroll onto the study. Specimens can be collected by surgical resection or biopsy of the primary tumor or biopsy or resection of a metastatic lesion.

  5. Age ≥18 years

  6. KPS ≥ 80

  7. Adequate hematologic and end organ function, defined by the following laboratory results obtained within 28 days prior to the first study treatment:

    1. ANC ≥ 1500 cells/μL (without granulocyte colony stimulating factor support within 4 weeks prior to Cycle 1, Day 1)
    2. WBC counts ≥ 2500/μL
    3. Absolute lymphocyte count ≥ 500/μL
    4. Platelet count ≥100,000/μL (without transfusion within 4 weeks prior to Cycle 1, Day 1)
    5. Hemoglobin ≥9.0 g/dL o Patients may be transfused or receive erythropoietic treatment to meet this criterion.
  8. AST, ALT, and alkaline phosphatase ≤ 2.5 x ULN, with the following exceptions:

    1. Patients with documented liver metastases: AST and/or ALT ≤ 5 x ULN
    2. Patients with documented liver or bone metastases: alkaline phosphatase ≤ 5 x ULN
  9. Serum bilirubin ≤ 1.5 x ULN

  10. Patients with known Gilbert disease who have serum bilirubin level ≤ 3 x ULN may be- enrolled.

  11. INR and aPTT ≤ 1.5 x ULN

    a. This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose.

  12. Creatinine ≤ 1.5 x ULN or Calculated Creatinine clearance ≥ 30mL/min by institutional standard measurement

  13. For women who are not postmenopausal (12 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use two adequate methods of contraception, including at least one method with a failure rate of ≥ 1% per year

  14. If any Grade ≥1 toxicities occurred in relation to prior treatment, patients must have recovered to baseline or ≤ Grade 1 unless adverse events are clinically insignificant or stable on supportive medication if needed.

Exclusion Criteria:

  1. Prior treatment with cabozantinib for RCC

  2. Receipt of any small molecule kinase inhibitor (including investigational) or VEGFtargeted therapy within 2 weeks before the first dose of study treatment

    o 2-week washout period was selected in order to facilitate rapid enrollment and treatment of patients given the target population with active brain metastases.

  3. Patients requiring whole brain radiotherapy (WBRT).

  4. Any prior brain radiotherapy within 28 days prior to enrollment

  5. Incomplete healing from prior radiotherapy as determined by the treating radiation oncologist or treating investigator

  6. Diagnosis of autoimmune condition that may worsen during immune checkpoint blockade, with the following exceptions:

    o Diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible.

  7. Any active or suspected autoimmune disease requiring systemic steroids > 10 mg daily prednisone (or equivalent) or other immunosuppression, except for:

    • those not expected to reoccur
    • Chronic physiologic replacement of ≤10mg prednisone (or equivalent) for treatment of adrenal insufficiency
    • Steroids required for pre-medication reactions
    • Local steroid use is permitted (e.g. intranasal, topical, inhaled, or local steroid injection, i.e. intra-articular)
  8. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures

  9. Uncontrolled hypercalcemia (≥ 1.5 mmol/L ionized calcium or Ca ≥ 12 mg/dL or corrected serum calcium ≥ ULN) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab

  10. Participation in an experimental drug study within 28 days of study enrollment

  11. Pregnant and lactating women

  12. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins

  13. Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within the previous 3 months, unstable arrhythmias, unstable angina, or EF < 50%

    o Patients with known coronary artery disease, congestive heart failure not meeting the above criteria must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate.

  14. Uncontrolled hypertension (>140 mm Hg systolic or >90 mm Hg diastolic) despite optimal antihypertensive treatment

  15. QTcF > 500 msec within 28 days before the first dose of study treatment

  16. Major surgical procedure within 14 days prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during the course of the study

    o Patients must have completed wound healing from major or minor surgery before first dose of study treatment

  17. History of stroke or transient ischemic attack within 6 months prior to Cycle 1, Day 1

  18. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Cycle 1, Day 1

  19. Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)

    o Clinically significant hematuria, hematemesis, or hemoptysis of >0.5 tsp (2.5ml) of red blood or other history of significant bleeding within 12 weeks before first dose of study treatment.

  20. Clinical signs or symptoms of gastrointestinal obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding

  21. Evidence of abdominal free air not explained by paracentesis or recent surgical procedure

  22. Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture

  23. Concomitant anticoagulation with coumarin agents, direct thrombin inhibitors, factor Xa inhibitor betrixaban, or platelet inhibitors. Other anticoagulants are allowed.

  24. Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose of study treatment.

    o Complete healing of intra-abdominal abscess must be confirmed before the first dose of study treatment

  25. Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation

  26. Lesions invading or encasing major blood vessels

  27. Uncompensated or symptomatic hypothyroidism

  28. History of solid organ or allogeneic stem cell transplant

  29. Clinically significant active infection including HIV, Hepatitis B, Hepatitis C, acute COVID-19 infection, or other

    • For patients with HIV infection, clinically significant/exclusionary features include: detectable viral load, CD4+ T cell count <300 cells/microL, or history of opportunistic infection
    • For patients with HBV infection, clinically significant/exclusionary features include: HBV surface antigen positivity, detectable HBV DNA by polymerase chain reaction (PCR). Patients with prior HBV infection (HBV core Ab positive, HBV DNA undetectable by PCR, HBV surface antigen negative) are eligible for the study if they are already stable on entecavir or tenofovir
  30. Inability to swallow tablets

  31. Previously identified allergy or hypersensitivity to components of the treatment

  32. Malignancy that requires anti-cancer directed therapy within the last 3 years. Exceptions include those cancers that are considered cured by local therapy (e.g. Basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of breast, bladder, or cervix) or other cancers that have low malignant potential and do not require systemic therapy (e.g. Gleason grade <6 prostate adenocarcinoma)

  33. Patients in whom nivolumab treatment is not otherwise feasible (for example, for financial reasons)

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Cabozantinib and Nivolumab With Radiation Therapy

Patients being newly initiated on cabo/nivo will be started on with cabozantinib 40 mg PO daily and nivolumab 480 mg IV day Q4 weeks

o Dose de-escalation of cabozantinib for toxicity will be allowed per prespecified toxicity dose levels

Radiation will be stereotactic radiosurgery, delivered over 1-5 fractions with a total dose of 18-30Gy depending on fractionation schedule per the discretion of the treating radiation oncologist. Standard institutional regimens such as 18-24 Gy in a single fraction, 24-27 Gy in three fractions, and 25-30 Gy in five fractions are permissible.

Cabozantinib (40 mg PO daily)

Nivolumab (480 mg IV Day 1)

Radiation will be stereotactic radiosurgery, delivered over 1-5 fractions with a total dose of 18-30Gy depending on fractionation schedule per the discretion of the treating radiation oncologist.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
percent of enrolled patients who are able to tolerate treatment
Ramy czasowe: 56-day

56-day safety monitoring period without unacceptable CNS toxicity. Unacceptable CNS toxicity is defined as any grade ≥3 treatment-emergent neurological disorder, per NCI CTCAE version 5.0 criteria

56-day

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
rate of CNS adverse events
Ramy czasowe: 1 year

CNS adverse events will be reported as a proportion of patients who experience a CNS adverse event of any grade based on CTCAE 5.0

1 year
objective response rate (ORR)
Ramy czasowe: 1 year

as measured by RANO-BM criteria

1 year

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Współpracownicy

Śledczy

  • Główny śledczy: Ritesh Kotecha, MD, Memorial Sloan Kettering Cancer Center

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

10 listopada 2023

Zakończenie podstawowe (Szacowany)

1 listopada 2027

Ukończenie studiów (Szacowany)

1 listopada 2027

Daty rejestracji na studia

Pierwszy przesłany

10 listopada 2023

Pierwszy przesłany, który spełnia kryteria kontroli jakości

10 listopada 2023

Pierwszy wysłany (Rzeczywisty)

15 listopada 2023

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

17 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

13 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

produkt wyprodukowany i wyeksportowany z USA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .